Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial, page-21

Yes.

So, I anticipate that we might not even see a clinically observable human reaction, even at the cut off point of 16,000 mg (which would be 4X an effective dose) for this trial.
The stated objective of this trial was to test for an "upper limit" before an observable reaction occurred. But, these trials cost money, and at some point you have to justify the ongoing expenditure. Recce have decided that, at this point in time, 16,000mg is a reasonable point to stop, assuming there are no reactions up to that dose.

I'm happy with that decision. Then, hopefully, we can move on to Phase 2 testing.

We can always revisit testing for an "upper limit", higher than 16,000mg at a later time.